Neurocrine Bioscience buy The Goldman Sachs Group, Inc.
Start price
25.01.24
/
50%
€128.55
Target price
25.01.25
€140.87
Performance (%)
9.80%
End price
26.01.25
€141.15
Summary
This prediction ended on 26.01.25 with a price of €141.15. The BUY prediction by The_Goldman_Sachs_Gr finished with a performance of 9.80%. The_Goldman_Sachs_Gr has a follow-up prediction for Neurocrine Bioscience where he still thinks Neurocrine Bioscience is a Buy. The_Goldman_Sachs_Gr has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y |
|---|---|---|---|
| Neurocrine Bioscience | 3.188% | 3.188% | 7.938% |
| iShares Core DAX® | -1,74 % | -10,68 % | -0,89 % |
| iShares Nasdaq 100 | -2,58 % | -3,32 % | 11,12 % |
| iShares Nikkei 225® | -1,16 % | -9,36 % | 23,69 % |
| iShares S&P 500 | -1,42 % | -3,76 % | 7,19 % |
Comments by The_Goldman_Sachs_Gr for this prediction
In the thread Neurocrine Bioscience diskutieren
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) had its price target raised by analysts at The Goldman Sachs Group, Inc. from $134.00 to $153.00. They now have a "buy" rating on the stock.
Ratings data for NBIX provided by MarketBeat
In the thread Trading Neurocrine Bioscience
Die von The_Goldman_Sachs_Gr gewählte maximale Laufzeit wurde überschritten
Current prediction by The_Goldman_Sachs_Gr for Neurocrine Bioscience
Neurocrine Bioscience
Start price
Target price
Perf. (%)
€114.40
10.07.25
10.07.25
€154.99
10.07.26
10.07.26
0.44%
26.03.26
26.03.26
